Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $124

Benzinga Newsdesk www.benzinga.com Negative 57.0%

Neg 57% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $152 to $124.